Related Experiment Videos
Influence of angiotensin-converting enzyme inhibition on cardiac function in myocardial infarction
G Ertl1, P Gaudron, K Kochsiek
1Medizinische Klinik, Universität Würzburg, Federal Republic of Germany.
Insights
Angiotensin-converting enzyme (ACE) inhibitors show promise in mitigating myocardial infarction (MI) damage. Studies suggest ACE inhibitors may improve cardiac function and reduce adverse remodeling in heart attack patients.
Area of Science:
- Cardiology
- Cardiovascular Research
- Pharmacology
Background:
- Cardiac function post-myocardial infarction (MI) is influenced by ischemic damage and residual myocardium's compensatory response.
- Reperfusion therapy in MI can occur at various stages, leading to stunned myocardium or irreversible necrosis.
- Residual myocardium adapts to injury through hypertrophy and dilatation, impacting overall cardiac output.
Purpose of the Study:
- To investigate the effects of Angiotensin-converting enzyme (ACE) inhibitors on cardiac function and remodeling following myocardial infarction (MI).
- To explore potential mechanisms by which ACE inhibitors may benefit patients at different stages of MI.
- To review current evidence and ongoing clinical trials regarding ACE inhibitors in ischemic heart disease.
Main Methods:
- Analysis of left ventricular dilatation and stroke volume changes over time in post-MI models.
- Review of experimental data on ACE inhibitor effects on lactate production, infarct size, and stunned myocardium.
- Examination of studies demonstrating ACE inhibitor impact on left ventricular dilatation and mortality in animal models of MI.
Main Results:
- Left ventricular dilatation progresses over time post-MI, with stroke volume initially increasing then plateauing, suggesting noncompensatory dilatation.
- ACE inhibitors have demonstrated benefits in reducing infarct size and improving recovery of stunned myocardium in experimental settings.
- Animal studies indicate ACE inhibitors reduce left ventricular dilatation and mortality after MI.
Conclusions:
- ACE inhibitors show potential for favorable effects across various stages of myocardial infarction (MI) by influencing cardiac remodeling and function.
- Further clinical evidence is required, but ongoing large-scale human studies aim to establish the role of ACE inhibitors in managing ischemic heart disease.
Abstract:
Cardiac function in myocardial infarction (MI) depends on the extent of damage in ischemic myocardium and the compensatory response of residual myocardium. Because thrombolytic therapy is performed in many patients, reperfusion of ischemic myocardium may take place at various stages of progression of the ischemic insult. If perfusion is reestablished before necrosis occurs, myocardium may recover immediately or after hours to weeks ("stunned myocardium"). If coronary occlusion persists, necrosis develops in the subendocardium, propagates transmurally and forms a scar after the healing phase. Residual myocardium responds to loss of contractile tissue and material properties of the ischemic zone by hypertrophy and dilatation. This study shows that left ventricular dilatation is accompanied by an increase in stroke volume from 4 days to 4 weeks; however, left ventricular dilatation progresses while stroke volume remains constant from 4 weeks to 6 months, suggestive of noncompensatory left ventricular dilatation. Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce lactate production after 60 seconds, and infarct size after 6 hours of coronary occlusion in dogs. Stunned myocardium recovers faster in animal experiments and pacing-induced myocardial ischemia may be prevented by ACE inhibitors. Left ventricular dilatation and mortality is reduced by ACE inhibitors in rats after MI. Several potential mechanisms are discussed to establish a favorable action of ACE inhibitors at various stages of MI. Clinical evidence is still pending; however, large studies are ongoing to clarify potential indications of ACE inhibitors in ischemic heart disease in humans.